Therapeutic targeting of B7-H1 in breast cancer

Bibliography

• Dermime S, Gilham DE, Shaw DM, Vaccine and antibody-directed T cell tumour immunotherapy. Biochim Biophys Acta 2004;1704(10):11-35
   PubMedGoogle Scholar
• Rivoltini L, Carrabba M, Huber V, Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol Rev 2002;188:97-113
   PubMed Web of Science ®Google Scholar
• Liu J, Hamrouni A, Wolowiec D, Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 2007;110(1):296-304
   PubMed Web of Science ®Google Scholar
• Dong H, Strome SE, Salomao DR, Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8(8):793-800
   PubMed Web of Science ®Google Scholar
• Wintterle S, Schreiner B, Mitsdoerffer M, Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res 2003;63(21):7462-7
   PubMed Web of Science ®Google Scholar
• Konishi J, Yamazaki K, Azuma M, B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 2004;10(15):5094-100
   PubMed Web of Science ®Google Scholar
• Ohigashi Y, Sho M, Yamada Y, Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 2005;11(8):2947-53
   PubMed Web of Science ®Google Scholar
• Nomi T, Sho M, Akahori T, Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 2007;13(7):2151-7
   PubMed Web of Science ®Google Scholar
• Thompson RH, Kuntz SM, Leibovich BC, Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006;66(7):3381-5
   PubMed Web of Science ®Google Scholar
• Hamanishi J, Mandai M, Iwasaki M, Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 2007;104(9):3360-5
   PubMed Web of Science ®Google Scholar
• Ghebeh H, Mohammed S, Al-Omair A, The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 2006;8(3):190-8
   PubMed Web of Science ®Google Scholar
• Liu SM, Meng Q, Zhang QX, Expression and significance of B7-H1 and its receptor PD-1 in human gastric carcinoma. Zhonghua Zhong Liu Za Zhi 2008;30(3):192-5
   PubMedGoogle Scholar
• Cao P, Cui Y, Liu Z, Expression and significance of PD-L1 in laryngocarcinoma. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2008;22(24):1115-16; 22
   PubMedGoogle Scholar
• Karim R, Jordanova ES, Piersma SJ, Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma. Clin Cancer Res 2009;15(20):6341-7
   PubMed Web of Science ®Google Scholar
• Zhao Q, Xiao X, Wu Y, Interleukin-17-educated monocytes suppress cytotoxic T cell function through B7-H1 in hepatocellular carcinoma patients. Eur J Immunol 2011;41(8):2314-22
   PubMedGoogle Scholar
• Crane CA, Panner A, Murray JC, PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer. Oncogene 2009;28(2):306-12
   PubMed Web of Science ®Google Scholar
• Ghebeh H, Tulbah A, Mohammed S, Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells. Int J Cancer 2007;121(4):751-8
   PubMed Web of Science ®Google Scholar
• Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008;8(6):467-77
   PubMed Web of Science ®Google Scholar
• Bell D, Chomarat P, Broyles D, In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med 1999;190(10):1417-26
   PubMed Web of Science ®Google Scholar
• Munz C, Steinman RM, Fujii S. Dendritic cell maturation by innate lymphocytes: coordinated stimulation of innate and adaptive immunity. J Exp Med 2005;202(2):203-7
   PubMed Web of Science ®Google Scholar
• Lutz MB, Kurts C. Induction of peripheral CD4+ T-cell tolerance and CD8+ T-cell cross-tolerance by dendritic cells. Eur J Immunol 2009;39(9):2325-30
   PubMed Web of Science ®Google Scholar
• Abbas AK, Sharpe AH. T-cell stimulation: an abundance of B7s. Nat Med 1999;5(12):1345-6
   PubMedGoogle Scholar
• Dong H, Zhu G, Tamada K, B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999;5(12):1365-9
   PubMed Web of Science ®Google Scholar
• Tokita D, Mazariegos GV, Zahorchak AF, High PD-L1/CD86 ratio on plasmacytoid dendritic cells correlates with elevated T-regulatory cells in liver transplant tolerance. Transplantation 2008;85(3):369-77
   PubMed Web of Science ®Google Scholar
• Kuipers H, Muskens F, Willart M, Contribution of the PD-1 ligands/PD-1 signaling pathway to dendritic cell-mediated CD4+ T cell activation. Eur J Immunol 2006;36(9):2472-82
   PubMed Web of Science ®Google Scholar
• Raimondi G, Shufesky WJ, Tokita D, Regulated compartmentalization of programmed cell death-1 discriminates CD4+CD25+ resting regulatory T cells from activated T cells. J Immunol 2006;176(5):2808-16
   PubMed Web of Science ®Google Scholar
• Hori J, Wang M, Miyashita M, B7-H1-induced apoptosis as a mechanism of immune privilege of corneal allografts. J Immunol 2006;177(9):5928-35
   PubMed Web of Science ®Google Scholar
• Pena-Cruz V, McDonough SM, Diaz-Griffero F, PD-1 on immature and PD-1 ligands on migratory human Langerhans cells regulate antigen-presenting cell activity. J Invest Dermatol 2010;130(9):2222-30
   PubMedGoogle Scholar
• Yao S, Wang S, Zhu Y, PD-1 on dendritic cells impedes innate immunity against bacterial infection. Blood 2009;113(23):5811-18
   PubMed Web of Science ®Google Scholar
• Rodriguez-Garcia M, Porichis F, de Jong OG, Expression of PD-L1 and PD-L2 on human macrophages is up-regulated by HIV-1 and differentially modulated by IL-10. J Leukoc Biol 2011;89(4):507-15
   PubMed Web of Science ®Google Scholar
• Freeman GJ, Long AJ, Iwai Y, Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000;192(7):1027-34
   PubMed Web of Science ®Google Scholar
• Fife BT, Pauken KE, Eagar TN, Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol 2009;10(11):1185-92
   PubMed Web of Science ®Google Scholar
• Morita M, Fujino M, Jiang G, PD-1/B7-H1 interaction contribute to the spontaneous acceptance of mouse liver allograft. Am J Transplant 2010;10(1):40-6
   PubMed Web of Science ®Google Scholar
• Liang S, Alard P, Zhao Y, Conversion of CD4+ CD25- cells into CD4+ CD25+ regulatory T cells in vivo requires B7 costimulation, but not the thymus. J Exp Med 2005;201(1):127-37
   PubMed Web of Science ®Google Scholar
• Ghebeh H, Barhoush E, Tulbah A, FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. BMC Cancer 2008;8:57
   PubMed Web of Science ®Google Scholar
• Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299(5609):1057-61
   PubMed Web of Science ®Google Scholar
• Kitazawa Y, Fujino M, Wang Q, Involvement of the programmed death-1/programmed death-1 ligand pathway in CD4+CD25+ regulatory T-cell activity to suppress alloimmune responses. Transplantation 2007;83(6):774-82
   PubMedGoogle Scholar
• Smigal C, Jemal A, Ward E, Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin 2006;56(3):168-83
   PubMed Web of Science ®Google Scholar
• Caras I, Grigorescu A, Stavaru C, Evidence for immune defects in breast and lung cancer patients. Cancer Immunol Immunother 2004;53(12):1146-52
   PubMed Web of Science ®Google Scholar
• Liyanage UK, Moore TT, Joo HG, Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002;169(5):2756-61
   PubMed Web of Science ®Google Scholar
• Pockaj BA, Basu GD, Pathangey LB, Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer. Ann Surg Oncol 2004;11(3):328-39
   PubMedGoogle Scholar
• Blank C, Gajewski TF, Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother 2005;54(4):307-14
   PubMed Web of Science ®Google Scholar
• Iwai Y, Ishida M, Tanaka Y, Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 2002;99(19):12293-7
   PubMed Web of Science ®Google Scholar
• Azuma T, Yao S, Zhu G, B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 2008;111(7):3635-43
   PubMed Web of Science ®Google Scholar
• Hirano F, Kaneko K, Tamura H, Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 2005;65(3):1089-96
   PubMed Web of Science ®Google Scholar
• Zhang P, Su DM, Liang M, Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis. Mol Immunol 2008;45(5):1470-6
   PubMed Web of Science ®Google Scholar
• Huang B, Zhao J, Li H, Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 2005;65(12):5009-14
   PubMed Web of Science ®Google Scholar
• Gallina G, Dolcetti L, Serafini P, Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest 2006;116(10):2777-90
   PubMed Web of Science ®Google Scholar
• Tamura M, Gu J, Matsumoto K, Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 1998;280(5369):1614-17
   PubMedGoogle Scholar
• Parsa AT, Waldron JS, Panner A, Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 2007;13(1):84-8
   PubMed Web of Science ®Google Scholar
• Wang L, Pino-Lagos K, de Vries VC, Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells. Proc Natl Acad Sci USA 2008;105(27):9331-6
   PubMed Web of Science ®Google Scholar
• Russo J, Ao X, Grill C, Pattern of distribution of cells positive for estrogen receptor alpha and progesterone receptor in relation to proliferating cells in the mammary gland. Breast Cancer Res Treat 1999;53(3):217-27
   PubMedGoogle Scholar
• Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19(5):403-10
   PubMed Web of Science ®Google Scholar
• Zhao Y, Huang Z, Qi M, Immune regulation of T lymphocyte by a newly characterized human umbilical cord blood stem cell. Immunol Lett 2007;108(1):78-87
   PubMedGoogle Scholar
• Schreiner B, Mitsdoerffer M, Kieseier BC, Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis. J Neuroimmunol 2004;155(1-2):172-82
   PubMed Web of Science ®Google Scholar
• Walker MR, Carson BD, Nepom GT, De novo generation of antigen-specific CD4+CD25+ regulatory T cells from human CD4+CD25- cells. Proc Natl Acad Sci USA 2005;102(11):4103-8
   PubMedGoogle Scholar
• Curiel TJ, Coukos G, Zou L, Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10(9):942-9
   PubMed Web of Science ®Google Scholar
• Bates GJ, Fox SB, Han C, Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006;24(34):5373-80
   PubMed Web of Science ®Google Scholar
• Hilsenbeck SG, Ravdin PM, de Moor CA, Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat 1998;52(1-3):227-37
   PubMedGoogle Scholar
• Shipitsin M, Campbell LL, Argani P, Molecular definition of breast tumor heterogeneity. Cancer Cell 2007;11(3):259-73
   PubMed Web of Science ®Google Scholar
• Lal G, Yin N, Xu J, Distinct inflammatory signals have physiologically divergent effects on epigenetic regulation of foxp3 expression and treg function. Am J Transplant 2011;11(2):203-14
   PubMed Web of Science ®Google Scholar
• Onizuka S, Tawara I, Shimizu J, Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 1999;59(13):3128-33
   PubMed Web of Science ®Google Scholar
• Dong H, Strome SE, Matteson EL, Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. J Clin Invest 2003;111(3):363-70
   PubMedGoogle Scholar
• Seo SK, Seo HM, Jeong HY, Co-inhibitory role of T-cell-associated B7-H1 and B7-DC in the T-cell immune response. Immunol Lett 2006;102(2):222-8
   PubMedGoogle Scholar
• Carter L, Fouser LA, Jussif J, PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol 2002;32(3):634-43
   PubMed Web of Science ®Google Scholar
• Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 2006;107(6):2409-14
   PubMed Web of Science ®Google Scholar
• Yang ZZ, Novak AJ, Stenson MJ, Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood 2006;107(9):3639-46
   PubMed Web of Science ®Google Scholar
• Barber DL, Wherry EJ, Masopust D, Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006;439(7077):682-7
   PubMed Web of Science ®Google Scholar
• Zabala M, Lasarte JJ, Perret C, Induction of immunosuppressive molecules and regulatory T cells counteracts the antitumor effect of interleukin-12-based gene therapy in a transgenic mouse model of liver cancer. J Hepatol 2007;47(6):807-15
   PubMed Web of Science ®Google Scholar
• Martinez-Lacaci I, Garcia Morales P, Soto JL, Tumour cells resistance in cancer therapy. Clin Transl Oncol 2007;9(1):13-20
   PubMedGoogle Scholar
• Weiss RB. The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 1992;19(6):670-86
   PubMed Web of Science ®Google Scholar
• Apetoh L, Mignot G, Panaretakis T, Immunogenicity of anthracyclines: moving towards more personalized medicine. Trends Mol Med 2008;14(4):141-51
   PubMed Web of Science ®Google Scholar
• Clarke M, Collins R, Darby S, Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365(9472):1687-717
   PubMed Web of Science ®Google Scholar
• Maccubbin DL, Wing KR, Mace KF, Adriamycin-induced modulation of host defenses in tumor-bearing mice. Cancer Res 1992;52(13):3572-6
   PubMedGoogle Scholar
• Ehrke MJ, Ryoyama K, Cohen SA. Cellular basis for adriamycin-induced augmentation of cell-mediated cytotoxicity in culture. Cancer Res 1984;44(6):2497-504
   PubMedGoogle Scholar
• Haskill JS. Adriamycin-activated macrophages as tumor growth inhibitors. Cancer Res 1981;41(10):3852-6
   PubMedGoogle Scholar
• Obeid M, Tesniere A, Ghiringhelli F, Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007;13(1):54-61
   PubMed Web of Science ®Google Scholar
• Apetoh L, Ghiringhelli F, Tesniere A, Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007;13(9):1050-9
   PubMed Web of Science ®Google Scholar
• Ghebeh H, Lehe C, Barhoush E, Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule. Breast Cancer Res 2010;12(4):R48
   Google Scholar
• Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999;57(7):727-41
   PubMed Web of Science ®Google Scholar
• Schwartz HS, Grindey GB. Adriamycin and daunorubicin: a comparison of antitumor activities and tissue uptake in mice following immunosuppression. Cancer Res 1973;33(8):1837-44
   PubMed Web of Science ®Google Scholar
• Minotti G, Menna P, Salvatorelli E, Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004;56(2):185-229
   PubMed Web of Science ®Google Scholar
• Vereecque R, Saudemont A, Quesnel B. Cytosine arabinoside induces costimulatory molecule expression in acute myeloid leukemia cells. Leukemia 2004;18(7):1223-30
   PubMed Web of Science ®Google Scholar
• Mokyr MB, Kalinichenko TV, Gorelik L, Importance of the B7-2 molecule for low dose melphalan-induced acquisition of tumor-eradicating immunity by mice bearing a large MOPC-315 tumor. J Immunol 1998;160(4):1866-74
   PubMedGoogle Scholar
• Casares N, Pequignot MO, Tesniere A, Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005;202(12):1691-701
   PubMed Web of Science ®Google Scholar
• Liang M, Yang H, Fu J. Nimesulide inhibits IFN-gamma-induced programmed death-1-ligand 1 surface expression in breast cancer cells by COX-2 and PGE2 independent mechanisms. Cancer Lett 2009;276(1):47-52
   PubMedGoogle Scholar
• Blank C, Brown I, Peterson AC, PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res 2004;64(3):1140-5
   PubMed Web of Science ®Google Scholar
• Blank C, Kuball J, Voelkl S, Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer 2006;119(2):317-27
   PubMed Web of Science ®Google Scholar
• Zang X, Allison JP. The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res 2007;13(18 Pt 1):5271-9
   PubMed Web of Science ®Google Scholar
• Currie AJ, Prosser A, McDonnell A, Dual control of antitumor CD8 T cells through the programmed death-1/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: regulation and counterregulation. J Immunol 2009;183(12):7898-908
   PubMed Web of Science ®Google Scholar
• Curigliano G, Spitaleri G, Dettori M, Vaccine immunotherapy in breast cancer treatment: promising, but still early. Expert Rev Anticancer Ther 2007;7(9):1225-41
   PubMed Web of Science ®Google Scholar
• Webster WS, Thompson RH, Harris KJ, Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine. J Immunol 2007;179(5):2860-9
   PubMed Web of Science ®Google Scholar
• Rosenblatt J, Glotzbecker B, Mills H, PD-1 Blockade by CT-011, Anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother 2011;34(5):409-18
   PubMed Web of Science ®Google Scholar
• Saudemont A, Jouy N, Hetuin D, NK cells that are activated by CXCL10 can kill dormant tumor cells that resist CTL-mediated lysis and can express B7-H1 that stimulates T cells. Blood 2005;105(6):2428-35
   PubMed Web of Science ®Google Scholar
• Benson DM Jr, Bakan CE, Mishra A, The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 2010;116(13):2286-94
   PubMed Web of Science ®Google Scholar
• Qiu H, Liu S, Xie C, Regulating immunity and inhibiting tumor growth by the recombinant peptide sPD-1-CH50. Anticancer Res 2009;29(12):5089-94
   PubMedGoogle Scholar
• Brahmer JR, Drake CG, Wollner I, Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010;28(19):3167-75
   PubMed Web of Science ®Google Scholar
• Hannon GJ. RNA interference. Nature 2002;418(6894):244-51
   PubMed Web of Science ®Google Scholar
• Borkner L, Kaiser A, van de Kasteele W, RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells. Cancer Immunol Immunother 2010;59(8):1173-83
   PubMedGoogle Scholar
• Liu X, Madhankumar AB, Slagle-Webb B, Heavy chain ferritin siRNA delivered by cationic liposomes increases sensitivity of cancer cells to chemotherapeutic agents. Cancer Res 2011;71(6):2240-9
   PubMed Web of Science ®Google Scholar
• Haile ST, Bosch JJ, Agu NI, Tumor cell programmed death ligand 1-mediated T Cell suppression is overcome by coexpression of CD80. J Immunol 2011;186(12):6822-9
   PubMed Web of Science ®Google Scholar
• Crane C, Panner A, Pieper RO, Honokiol-mediated inhibition of PI3K/mTOR pathway: a potential strategy to overcome immunoresistance in glioma, breast, and prostate carcinoma without impacting T cell function. J Immunother 2009;32(6):585-92
   PubMed Web of Science ®Google Scholar
• Liang M, Fu J. Triptolide inhibits interferon-gamma-induced programmed death-1-ligand 1 surface expression in breast cancer cells. Cancer Lett 2008;270(2):337-41
   PubMed Web of Science ®Google Scholar
• Berthon C, Driss V, Liu J, In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors. Cancer Immunol Immunother 2010;59(12):1839-49
   PubMed Web of Science ®Google Scholar
• Cleator S, Parton M, Dowsett M. The biology of neoadjuvant chemotherapy for breast cancer. Endocr Relat Cancer 2002;9(3):183-95
   PubMedGoogle Scholar